FDA Green Lights Medtronic’s MRI-Conditional Cardiac Resynchronization Therapy Defibrillators

Medtronic was blessed with FDA approval for the first and only magnetic resonance imaging conditional cardiac resynchronization therapy defibrillators, the company announced.

The Amplia MRI Quad CRT-D SureScan and Compia MRI Quad CRT-D SureScan systems are approved for MRI scans on any part of the body without positioning restrictions.

U.S. patients who receive these devices — which help treat their heart failure and reduce their risk of sudden cardiac arrest — now will have access to MRI scans if and when they need them. Both CRT-D systems will be commercially available in the coming months. — Jonathon Shacat